Company Profile
Scancell’s mission is to deliver potent and safe active immunotherapies for a cancer-free future. Our Immunobody® and Moditope® active immunotherapies are off-the-shelf treatments designed to deliver favourable safety, low toxicity and durable systemic immune responses. Our lead product iSCIB1+, an Immunobody® DNA active immunotherapy, activates a strong and safe lasting immune response in patients with advanced melanoma, with the potential to set a new benchmark in the standard of care. The lead Moditope® peptide active immunotherapy has also shown encouraging Phase 2 data in a broad range of solid tumors.
Scancell’s wholly owned subdisiary, Glymab Therapeutics Ltd., has two antibody technologies, GlyMab® (anti-glycans) and AvidiMab®, with the potential to treat many solid cancers. GlyMab® antibodies targets glycans or sugars that are added onto proteins and / or lipids are supported by comprehensive preclinical data, resulting in two partnering deals with Genmab.
Scancell is incorporated in the UK where its main operations are located.
About Scancell
Scancell (LSE:SCLP;) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified – enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.